Published in Gene Therapy Weekly, September 20th, 2001
Current drug therapy is only partially successful at reducing cardiac hypertrophy, noted T. Nozato and colleagues working in Japan. They studied p16(INK4a) in vitro and in the rat model to see if it offered a better alternative.
"Adenovirus-mediated overexpression of p16(INK4a) completely inhibited cardiac myocyte hypertrophy induced by endothelin (ET)-1, as evaluated by [H-3]leucine incorporation into the cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.